Jove
Visualize
Contact Us

Related Experiment Videos

WITHDRAWN: Eletriptan for acute migraine.

L A Smith1, A D Oldman, H J McQuay

  • 1Oxford Brookes University, School of Health and Social Care, Jack Straws Lane, Marston, Oxford, UK, OX3 0FL. lesleysmith@brookes.ac.uk

The Cochrane Database of Systematic Reviews
|July 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Using Advanced Cell Culture Techniques to Differentiate Pluripotent Stem Cells and Recreate Tissue Structures Representative of Teratoma Xenografts.

Frontiers in cell and developmental biology·2021
Same author

Applications of novel bioreactor technology to enhance the viability and function of cultured cells and tissues.

Interface focus·2020
Same author

Ubiquitous parasites drive a 33% increase in methane yield from livestock.

International journal for parasitology·2018
Same author

To fill or not to fill: a qualitative cross-country study on dentists' decisions in managing non-cavitated proximal caries lesions.

Implementation science : IS·2018
Same author

Correction to: Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy.

BMC anesthesiology·2017
Same author

Can BAPEN do more to advance nutrition training amongst trainee doctors? Results of the first UK BAPEN medical trainee group survey.

Clinical nutrition ESPEN·2017
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Eletriptan effectively treats acute migraine attacks, with benefits increasing at higher doses. While generally well-tolerated, higher doses of eletriptan (e.g., 80mg) are associated with more minor adverse effects compared to lower doses.

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Migraine Treatment

Background:

  • Eletriptan (Relpax) is a novel triptan for acute migraine treatment.
  • Several triptans are available, necessitating comparative efficacy data.
  • Evidence-based assessments are crucial for selecting optimal migraine therapies.

Purpose of the Study:

  • To evaluate eletriptan's efficacy for acute migraine relief.
  • To assess headache response and pain-free outcomes at various time points.
  • To determine the number-needed-to-treat (NNT) and number-needed-to-harm (NNH) for eletriptan.

Main Methods:

  • Analysis of Phase III randomized, placebo-controlled trials provided by the manufacturer.
  • Inclusion criteria: double-blind, placebo-controlled trials for acute migraine in adults.

Related Experiment Videos

  • Data extraction and quality scoring by two independent reviewers; calculation of relative benefit and NNT/NNH.

    • Main Results:

    • Eletriptan (20mg, 40mg, 80mg) demonstrated significant efficacy over placebo for headache and pain-free responses at 2 hours.
    • NNTs for pain-free response at 2 hours were 9.9, 4.0, and 3.7 for 20mg, 40mg, and 80mg, respectively.
    • Minor adverse effects were dose-dependent and significantly higher with eletriptan than placebo, with no major harm observed.

    Conclusions:

    • Eletriptan (20mg, 40mg, 80mg) is effective for acute migraine treatment.
    • Efficacy is dose-related, with improved pain-free response and 24-hour outcomes at higher doses.
    • Eletriptan is well-tolerated as a single dose, comparing favorably with other triptans, though higher doses increase minor adverse effects.